Baxter wins FDA approval for another hemophilia drug

Baxter ($BAX) widened its hemophilia franchise on the eve of its breakup, winning FDA approval for a drug that treats a rare form of the bleeding disorder. Obizur is a treatment for acquired hemophilia A that works by replacing Factor VIII, the missing or deficient protein that keeps patients' blood from properly clotting. Unlike inherited forms of the disease, acquired hemophilia A develops later in life from a variety of causes and affects only about one in a million people, according to Baxter. The latest approval comes as the company plans to split in two next year, keeping its med tech business under the old name and hiving off its biopharma operation into a new firm called Baxalta. FDA release | Baxter release

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.